Ever Supreme Advances CAR001 Therapy to Phase IIa Trials

The transition to Phase IIa follows a Phase I dose-escalation study that reported an excellent safety profile and early signs of efficacy in treatment-resistant solid tumors. Notably, researchers observed a complete response in a glioblastoma patient and significant tumor reduction in a case of microsatellite stable colorectal cancer. Unlike traditional autologous CAR-T treatments, this allogeneic gamma-delta T cell platform eliminates the need for lymphodepletion, a preparatory chemotherapy that often causes severe toxicity and immune suppression.

By bypassing chemotherapy, the therapy preserves the patient's existing immune environment, allowing the drug's bispecific T-cell engager mechanism to recruit the patient's own immune cells for a synergistic attack against tumors. This off-the-shelf approach addresses critical manufacturing bottlenecks, such as inconsistent cell quality and long wait times associated with patient-specific treatments. Ever Supreme plans to utilize the upcoming trial data to satisfy international licensing requirements and explore conditional approval pathways under Taiwan’s Regenerative Medicine Acts. The company aims to leverage these clinical milestones to secure global pharmaceutical partnerships and launch multi-center, multi-country Phase IIb trials.